SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) announced today positive new clinical data on NEUMUNE™ (HE2100) from a study designed to evaluate the safety and hematopoietic activity of the compound in healthy adult and elderly adult human volunteers. The findings have important potential implications for the mitigation of both Acute Radiation Syndrome (ARS) and nosocomial (healthcare-associated) infections -- two indications for which NEUMUNE is currently being developed under open INDs. The data are being presented at a late-breaker session of the 44th Annual Meeting of the Infectious Disease Society of America (“IDSA”) held October 12-15, 2006, in Toronto, Ontario.
